CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Regulation FD disclosure
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Open-market buy Director bought 660 shares at $23.70 ($15,639)
- 4 Open-market sale Chief Accounting Officer sold 150,000 shares at an average $25.83 ($3,874,017)
- 4 Open-market buy Director bought 1,260 shares at $24.99 ($31,487)
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Accounting Officer sold 18,073 shares at $25.09 ($453,452)
- 4 Option exercise Chief Accounting Officer acquired 18,073 shares (option exercise)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure
- 4 Open-market sale Chief Accounting Officer sold 8,269 shares at $24.86 ($205,567)
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Scientific Officer sold 100,000 shares at an average $24.72 ($2,471,640)
- 144 Insider Sale of Securities
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 8-K Event Regulation FD disclosure · Other events
Page 5 of 21 · 415 filings